Aprea Therapeutics (NASDAQ:APRE) Releases Earnings Results

Aprea Therapeutics (NASDAQ:APRE) announced its earnings results on Monday. The company reported ($0.32) earnings per share for the quarter, FiscalAI reports. Aprea Therapeutics had a negative net margin of 2,666.46% and a negative return on equity of 88.12%. The company had revenue of $0.00 million for the quarter.

Aprea Therapeutics Price Performance

NASDAQ:APRE opened at $0.74 on Monday. The firm has a market capitalization of $5.14 million, a P/E ratio of -0.34 and a beta of 1.42. Aprea Therapeutics has a one year low of $0.55 and a one year high of $2.65. The company’s 50-day simple moving average is $0.80 and its 200 day simple moving average is $1.12.

Analyst Upgrades and Downgrades

Several brokerages have commented on APRE. HC Wainwright restated a “buy” rating and issued a $4.00 price objective (down from $5.00) on shares of Aprea Therapeutics in a report on Thursday, January 29th. Zacks Research raised Aprea Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, February 16th. Weiss Ratings restated a “sell (e+)” rating on shares of Aprea Therapeutics in a research note on Wednesday, January 21st. Finally, Wedbush dropped their price target on Aprea Therapeutics from $11.00 to $7.00 and set an “outperform” rating on the stock in a research report on Tuesday, February 10th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Aprea Therapeutics currently has an average rating of “Hold” and an average target price of $5.50.

Hedge Funds Weigh In On Aprea Therapeutics

An institutional investor recently bought a new position in Aprea Therapeutics stock. Jane Street Group LLC purchased a new position in Aprea Therapeutics, Inc. (NASDAQ:APRE) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 46,621 shares of the company’s stock, valued at approximately $40,000. Jane Street Group LLC owned about 0.67% of Aprea Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 34.19% of the company’s stock.

About Aprea Therapeutics

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.